Edited by: Thomas Bieber
A prospective study on the safety of sublingual immunotherapy in pregnancy
Version of Record online: 5 APR 2012
© 2012 John Wiley & Sons A/S
Volume 67, Issue 6, pages 741–743, June 2012
How to Cite
Shaikh WA, Shaikh SW. A prospective study on the safety of sublingual immunotherapy in pregnancy. Allergy 2012; 67: 741–743.
- Issue online: 10 MAY 2012
- Version of Record online: 5 APR 2012
- Manuscript Accepted: 17 FEB 2012
The aim of this study was to determine the safety of sublingual immunotherapy in pregnancy, which has not yet been reported.
One hundred and fifty-five patients received sublingual immunotherapy with either house dust mite (D. farinae) or a mixture of up to five allergens during 185 pregnancies. Twenty-four patients received sublingual immunotherapy for the first time during pregnancy. Follow-up data were analysed with regard to abortion, perinatal mortality, prematurity, toxaemia and congenital malformation. Two control groups did not receive immunotherapy; group A (85 patients) received budesonide 400 μg twice daily and group B (40 patients) received rescue salbutamol inhalation. All three groups were on appropriate avoidance measures.
Six-year follow-up data for the sublingual immunotherapy group revealed an incidence of complications less than that in the general population and a higher incidence of complications in both control groups.
This study concludes that sublingual immunotherapy is safe during pregnancy and is also safe when initiated for the first time in a pregnant patient.